natgillin/translations-raw huggingface dataset:
Use according to claim 12, wherein the cell comprises: a human light chain variable immunoglobulin region gene sequence encoding a human immunoglobulin light chain variable domain derived from a human Vk1-39Jk gene segment, wherein the human immunoglobulin light chain variable region gene sequence is fused, directly or through a linker, to a human immunoglobulin light chain constant region gene sequence, resulting in a gene encoding a human immunoglobulin light chain; 
(a) genski odsječak varijabilne regije lakog lanca humanog imunoglobulina koji kodira varijabilnu domenu lakog lanca humanog imunoglobulina izvedenu iz humanog segmenta gena VK1-39JK, pri čemu je genski odsječak varijabilne regije lakog lanca humanog imunoglobulina spojen izravno ili preko povezivača, na genski odsječak nepromjenjive regije lakog lanca humanog imunoglobulina, čime se dobiva gen koji kodira laki lanac humanog imunoglobulina;
Liquid compositions, such as suspensions or solvents contain the Zn-HA complex active ingredient in a suitable liquid carrier, e. g. in an aqueous solvent, such as water, ethanol or glycerol, or in a non-aqueous solvent, such as polyethylene glycol or an oil, or a mixture thereof. 
Tekući sastavi poput suspenzija ili otapala sadrže Zn-HA kompleks aktivnog sredstva u prikladnom tekućem nosaču, tj. u vodenom otapalu, poput vode, etanola ili glicerola, ili u ne-vodenom otapalu, poput polietilen glikola ili ulja, ili njihove smjese.
The process of claim 10, wherein the suitable oxime formation conditions comprise a two step sequence, wherein the two step sequence comprises a first step of deprotecting the ketal group in the compound of formula 3b: under suitable deprotection conditions to provide the corresponding aldehyde, and a second step of subjecting the corresponding aldehyde to suitable oxime formation conditions. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da pogodni uvjeti stvaranja oksima sadržavaju sekvencu u dva koraka, pri čemu sekvenca u dva koraka sadržava prvi korak uklanjanja zaštite ketalne skupine u spoju formule 3b: be Bac EN
The pharmaceutical composition for use according to any of claim 8 - 12, wherein said tumor diseases are solid tumors, preferably epithelial tumors, such as prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, such as colon carcinoma; kidney cancer; thyroid carcinoma; uterine carcinoma; or adrenal carcinoma. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 17 ili 18, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poput karcinoma prostate; karcinoma dojke; karcinoma gušterače; karcinoma pluća; karcinoma gastrointestinalnog sustava, poput karcinoma debelog crijeva; raka bubrega; karcinoma štitnjače; karcinoma maternice; karcinoma nadbubrežne žlijezde.
The process of claim 36, wherein the vaccine is a trivalent influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest monovalentno cjepivo protiv pandemijske gripe.
assessing the level of expression of the marker protein encoded by the marker gene or the combination of marker proteins encoded by the marker genes in a plurality of biological samples, wherein the biological samples are blood serum, from patients before treatment with the HER dimerization inhibitor, 
- < amfiregulin-marker-genom, marker-genom faktora epidermalnog rasta, marker-genom alfa faktora transformacije rasta i HER2-marker-genom, u biološkom uzorku od pacijenta, pri čemu je biološki uzorak krvni serum, i b) predviđanje reakcije na liječenje inhibitorom HER dimerizacije kod pacijenta pomoću procjene rezultata iz koraka a).
The apparatus of clause 1, wherein the separation element is integral with at least one of the body and the cover. 
Uređaj prema jednom od patentnih zahtjeva 1 do 8, pri čemu je element (1) odvajanja integralan sa najmanje jednim od tijela i poklopcem.
Res., 42:335-342 (1977), 1 mg/ml concentrations of WTPM were admixed with the S-9 activating system, plus the standard Ames bacterial cells, and incubated at 37°C for twenty minutes. 
Res. 42:335-342 (1977), koncentracije od 1 mg/ml MUČM mješaju se sa S-9 aktivacijskira sustavom, plus sa standardnim Ames bakterijskim ćelijama, inkubiraju se na 37%C tokom 20 minuta.
This chamber was fixed to the stage of an inverted, phase-contrast microscope. 
Ova je komorica potom učvršćena na postolje fazno-kontrastnog mikroskopa.
Example 1: Preparation of the composition 
Datum podnošenja europske prijave patenta:
The fibers according to any one of claims 1-3, containing 1 g or less of said nano-sized diamond and 10 mg or less of said platinum nanocolloid per 1 kg of said fibers. 
Vlakna u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačena time što sadrže 1 g ili manje navedenog dijamanta nano-veličine i 10 mg ili manje navedenog platinskog nanokoloida po 1 kg navedenih vlakana.
The antibody for use according to any one of claims 17, 20, and 21, wherein the condition is bone disease resulting in loss of bone mass, and wherein the antibody is administered in combination with a further therapeutic agent selected from a bone growth promoting (anabolic) agent and a bone anti-resorptive agent. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 17, 20 1 21, naznačeno time što je stanje bolest kostiju, koja ima za posljedicu gubitak koštane mase, te gdje se protutijelo primijenjuje u kombinaciji s dodatno terapijsko sredstvo, koje se bira između sredstva koje potiče rast kostiju (anaboličkog) i sredstva protiv resorpcije kostiju.
The use of Claim 17 wherein the medical condition is selected from the group consisting of irritable bowel syndrome, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, post-operative ileus, intestinal pseudo-obstruction, and drug-induced delayed transit. 
Uporaba iz Patentnog zahtjeva 17, naznačena time, daje medicinsko stanje odabrano iz skupine koju čine: sindrom iritabilnog crijeva, kronični zatvor, funkcionalna dispepsija, odgođeno pražnjenje želuca, gastroezofagalna refluksna bolest, gastropareza, postoperacijski ileus, intestinatna pseudoopstrukcija i usporeni tranzit crijevnog sadržaja uzrokovan lijekovima.
The method of claim 58, wherein the tauopathy is Alzheimer's disease. 
Antitijelo ili farmaceutski pripravak za uporabu prema zahtjevu 17, pri čemu tauopatija je Alzheimerova bolest.
The method of claim 9, wherein the medium comprises: DMEM/F12 basal medium at a concentration of 1x; neurobasal medium at a concentration of 1x; penicillin/streptomycin at a concentration of 1%; L-Glutamine at a concentration of 4 mM; 2-mercaptoethanol at a concentration of 0.1 mM; N2 supplement at a concentration of 1x; B27 supplement at a concentration 1x; LIF at a concentration of 100U/mL; PD0325901 at a concentration of 1 µM, and CHIR99021 at a concentration of 3 µM. 
Postupak sukladno patentnom zahtjevu 9, naznačen time, da medij sadrži: DMEM/F12 bazalni medij u koncentraciji od 1x; neuro-bazalni medij u koncentraciji od 1x; penicilin/streptomicin u koncentraciji od 1%; L- glutamin u koncentraciji od 4mM; 2-merkaptoetanol u koncentraciji od 0,1 mM; N2 suplement u koncentraciji od 1x; B27 suplement u koncentraciji od 1x; LIF u koncentraciji od 100U/ml; PD0325901 u koncentraciji od 1 uM1 CHIR99021 u koncentraciji od 3,0 uM.
A crystalline form (Form C) according to claim 1 further having a diffraction peak at a diffraction angle (2θ ± 0.2°) of 19.1° in a powder X-ray diffraction. 
Kristalni oblik (Oblik C) u skladu s patentnim zahtjevom 1, naznačen time, da je osim toga njegov difrakcijski maksimum na kutu difrakcije (20 + 0.2%) od 19,1" u rentgenskoj difrakciji praška.
In particular the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan 1 dijabetes neovisan o inzulinu.
According to a first aspect of the present invention, there is provided a process for the manufacture of a compound of the Formula IIa from a (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III: 
PATENTNI ZAHTJEVI 5 1. Postupak za dobivanje spoja formule IIa: naznačen time da R je pogodan sulfonatni ester; iz(C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III:
The skilled person can readily determine regions of IL-2 that can tolerate change, based on natural variation, alignments of active forms of proteins, etc., and substituted proteins can be tested for biological activity e.g. 
Stručna osoba iz odgovarajućeg područja može odmah odrediti regije od IL-2 koje mogu tolerirati promjenu, bazirano na prirodnom variranju, rasporedu aktivnih oblika proteina, i t.d., a supstituirani proteini se mogu testirati na biološku aktivnost, na pr.
interpret messages from the SIP Proxy Server to manage DMR signalling/data/voice features toward DMR Terminals, and 
- interpretaciju poruka SIP proksi servera radi upravljanja DMR signalizacijskim/podatkovnim/glasovnim obilježjima HR P20170696 T1 prema terminalima DMR, i
treating Compound 9 with a lower alkyl carbonyl compound and a carbonate base in a biphasic solvent system to produce purified Compound 8; 
(c) obradi Spoja 9 nižim alkilkarbonilnim spojem i karbonatnom bazom u dvofaznom sustavu otapala kako bi so dobilo pročišćeni Spoj 8;
Use of an effective amount of a compound of claim 1 or claim 20 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pain, urinary incontinence, an ulcer, irritable-bowel syndrome or inflammatory-bowel disease. 
Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol za uporabu kod liječenja boli, urinarne inkontinencije, čira, sindroma iritabilnog crijeva ili upalnog poremećaja crijeva.
3 shows the structure of the cellulose gel after the first wash. 
(32) Datum podnošenja prve prijave: 14.10.2008.
The system of claim 1 wherein the electric heater comprises a hollow tubular structure. 
Sustav (10) prema zahtjevu 1, pri čemu je električni grijač (14) električni grijač cijevastog oblika, koji obuhvaća šuplju strukturu cijevastog oblika.
R4y is hydrogen, C1-4 alkyl, C1-4 fluoroalkyl, C6-10 ar(C1-4)alkyl, the aryl portion of which may be optionally substituted, or an optionally substituted 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring; or 
y je vodik, C1-4 alkil, C1-4 fluoralkil, C6-10 ar(C1-4)alkil, čiji arilni dio može biti izborno supstituiran, ili izborno supstituirani 5- ili 6-eročlani aril, heteroaril ili heterociklil prsten; ili
providing a cation exchange resin and an anion exchange resin, wherein the cation exchange resin is regenerated in acid form, and wherein the anion exchange resin is regenerated in alkali form; 
Postupak prema patentnom zahtjevu 1, naznačen time što se smola za izmjenu kationa regenerira u kiseloj formi, i / ili gdje se smola za izmjenu aniona regenerira u alkalnom obliku.
rapidly cooling the solution so as to form crystals of said compound; and isolating the crystals. 
brzo hlađenje otopine tako da se dobiju kristali spomenutog spoja; i
The anti-VEGF antagonist antibody and/or anti-alpha5betal antagonist antibody for use according to any one of claims 1-4, wherein the disease is selected from the group consisting of retinopathy, age-induced macular degeneration, rubeosis; psoriasis, psoriatic arthritis, an inflammatory renal disease, haemolytic uremic syndrome, diabetic nephropathy, arthritis, inflammatory bowel disease, chronic inflammation, chronic retinal detachment, chronic uveitis, chronic vitritis, corneal graft rejection, corneal neovascularization, corneal graft neovascularization, Crohn's disease, myopia, ocular neovascular disease, osteoarthritis, Paget's disease, pemphigoid, polyarteritis, post-laser radial keratotomy, retinal neovascularization, Sjogren's syndrome, ulcerative colitis, graft rejection, lung inflammation, nephrotic syndrome, edema, ascites associated with malignancies, stroke, angiofibroma and neovascular glaucoma. 
Protutijelo antagonista anti-VEGE i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koju čine: retinopatija, makularna degeneracija izazvana starošću, rubeoza, psorijaza, psorijatični artritis, upalna bolest bubrega, sindrom hemolitičke uremije, dijabetička nefropatija, artritis, upalna bolest crijeva, kronično zapaljenje, kronično odvajanje bubrega, kronični uveitis, kronični vitritis, odbijanje usatka rožnice, neovaskularizacija rožnice, neovaskularizacija usatka rožnice, Chronova bolest, miopija, očna neovaskularna bolest, osteoartritis, Pagetova bolest, pemfigoid, poliarteritis, post- laserska radijalna keratotomija, retinalna neovaskularizacija, Sjorgenov sindrom, ulcerativni kolitis, odbijanje usadaka, upala pluća, nefrotički sindrom, edem, ascites povezani s malignim poremećajima, udar, angiofibrom i neovaskularni glaukom.
The process according to claim 1, wherein the heterogeneous acid catalyst is selected from the group consisting of: a sulfonic acid resin, a zeolite and a montmorillonite. 
Postupak prema zahtjevu 2 naznačen time što heterogeni kiseli katalizator je smola sulfonske Kiseline ili alternativno, odabrana je iz skupine koja sadrži: zeolit i montmorilonit.
The person operating the controls may not be in the best location on the boat to monitor the movement and position of the boat relative to the dock. 
Osoba koja se nalazi za upravljačkim kontrolama često nije u najboljem položaju na plovilu kako bi pratio kretanje i položaj plovila u odnosu na pristajalište.
The antibody or antigen binding portion thereof according to any one of claims 1 to 8 for use according to claim 20, wherein the anti-cancer small molecule is an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule-targeting agent, a kinase inhibitor, a protein synthesis inhibitor, an immunotherapeutic, a hormone or analog thereof, a somatostatin analog, a glucocortocoid, an aromatase inhibitor, an mTOR inhibitor, a small molecule targeting IGF1R or a small molecule targeting EGFR. 
drugo antitijelo je anti-IGF1R antitijelo, anti-EGFR antitelo ili anti-cmet antitijelo; ili (b) sredstvo je antimetabolit, alkirajuće sredstvo, inhibitor topoizomerase, sredstvo sa ciljanim djelovanjem na mikrotubule, inhibitor kinaze, inhibitor sinteze proteina, imunoterapeutik, hormon ili njegov analog, analog somatostatina, glukokortokoid, inhibitor aromatoze, inhibitor mTOR, mala molekula koja ciljano djeluje na IGF1R ili mala molekula koja ciljano djeluje na EGFR.
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed acute myeloid leukemia (AML) pediatric subject, to maintain remission in a pediatric subject, or a relapsed or refractory acute myeloid leukemia (AML) subject. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom pedijatrijskom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod pedijatrijskog subjekta ili subjekta s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
The method of claim 26, wherein the cancer is breast cancer, lung cancer, stomach cancer, intestinal cancer, renal cancer, melanoma or non-small cell lung cancer. 
PD-1 protutijelo ili fragment koji se vezuje na antigen sukladno bilo kojem od patentnih zahtjeva 1-6, ili farmaceutski pripravak sukladno patentnom zahtjevu 12 za liječenje karcinoma dojke, karcinoma pluća, karcinoma želuca, karcinoma crijeva, karcinoma bubrega, melanoma ili nesitnostaničnog karcinoma pluća.
t is 0 or 1 and when t is 0 then a direct bond is intended; 
tjeQili 1ikada tje 0 tada je namjeravana direktna veza;
A compound of formula (IV) as claimed in claim 1 or claim 4, wherein D is -O- and Ar1 and Ar2 are substituted or unsubstituted phenyl or het, wherein said het is substituted or unsubstituted pyrimidine, pyridine, oxazole or 2-methyloxazole 
Spojevi formule (IV) prema zahtjevu 1 ili 4, naznačeni time, da D je -O-, a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran pirimidin, piridin, oksazol ili 2-metiloksazol.
This medium also contained 4.5 g/l of glucose. 
Ovaj medij također sadrži 4.5 g/L glukoze.
Further, treatment of obesity is expected to prevent progression of medical covariants of obesity, such as arteriosclerosis, Type II diabetes, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, cholelithiasis and sleep disorders. 
Dalje, za liječenje gojaznosti se očekuje sprječavanje razvoja medicinskih vrsta gojaznosti kao što su arterioskleroza, dijabetes Tipa II, policistička oboljenja jajnika, kardiovaskularne bolesti, HR P20070267 T3 osteoartritis, dermatološki poremećaji, hipertenzija, otpornost na inzulin, hiperkolesterolemija, hipertrigliceridemija, kolelitijaza i poremećaji spavanja.
A package comprising a sealed container, wherein the sealed container comprises a moisture resistant material, a desiccant, and at least one dosage form of claims 14 or 15, wherein the desiccant and at least one dosage form are inside the sealed container; preferably wherein the moisture resistant material is selected from the group consisting of metal, glass, plastic, and metal coated plastic; and/or wherein the desiccant is selected from the group consisting of molecular sieves, clay, silica gel, activated carbon, and combinations thereof. 
Ambalaža koju čini zapečaćena posuda, naznačena time što zapečaćena posuda sadrži materijal otporan na vlagu, desikant i najmanje jednu doznu formu u skladu sa zahtjevima 9 do 13, naznačeno time što se desikant i najmanje jedna dozna forma nalaze unutar zapečaćene posude. Ambalaža u skladu sa zahtjevom 14, naznačena time što je materijal otporan na vlagu izabran iz grupe koja se sastoji od metala, stakla, plastike ili metalom obložene plastike.
The method of any of claims 24-39, further comprising, rinsing, shampooing, and/or conditioning the hair, wherein step (c) occurs subsequent to step (b). 
Postupak prema bilo kojem od zahtjeva 24-39, naznačen time da nadalje sadrži (c) ispiranje, šamponiranje i/ili regeneriranje kose, gdje se korak (c) javlja uzastopno nakon koraka (b).
wherein Rx has the meanings as given above, 
(Va), gdje Rx ima značenje kao gore određeno,
Process according to aspect 1, in which the corrugated surface of the frozen or deep-frozen food comprises more than two support points, alternating with two or more channels or arches. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da površina smrznutog ili duboko smrznutog prehrambenog proizvoda sadržava više od dvije potporne točke, naizmjence s dva ili više lukova.
Of particular effectiveness in the present invention are the targeted matrix in matrix systems comprising a formulation of a hydrophilic first matrix, comprising a lipophilic phase and an amphiphilic phase, wherein the lipophilic phase and the amphiphilic phase are in a second matrix together and the second matrix is dispersed throughout the hydrophilic first matrix and wherein the pharmaceutical composition containing the compound is at least partially incorporated into the amphiphilic phase. 
Smjesa prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, što je sistem za dostavu koji cilja debelo crijevo, sistem "matriks u matriksu", što je formulacija sa kontroliranim oslobađanjem načinjena od hidrofilnog prvog matriksa koji sadrži lipofilnu fazu i amfifilnu fazu, pri čemu su lipofilna faza 1 amfifilna faza zajedno u drugom matriksu i navedeni drugi matriks je disperziran kroz hidrofilni prvi matriks, i gdje je spoj bar dijelom inkorporiran u amfifilnu fazu.
reacting said compound of formula L with to form a compound of formula R: wherein R2 is as defined for the compound of formula V, 
[image] pri čemu R2 je definiran za spoj formule V; reakcije navedenog spoja formule L s [image] tvoreći spoj formule R:
Examples of alkenyl group having 8 to 20 carbons include straight or branched octenyl, nonenyl, decenyl, undecenyl, dodecenyl and tridecenyl groups or the like. w represents on average any integer in the range of 1 to 25, x represents on average any integer in the range of 1 to 25, y represents on average any integer in the range of 1 to 25, and z represents on average any integer in the range of 1 to 25. 
(D gdje, EO predstavlja etilenoksi skupinu, PO predstavlja propilenoksi skupinu, R predstavlja alkil ili alkenil skupinu sa 8 do 20 ugljika, w predstavlja u prosjeku cijeli broj u rasponu od 1 do 25, x predstavlja u prosjeku cijeli broj u rasponu od 1 do 25, y predstavlja u prosjeku cijeli broj u rasponu od 1 do 25, i z predstavlja u prosjeku cijeli broj u rasponu od 1 do 25, u kombinaciji s pesticidnom djelatnom tvari gdje je ta pesticidna djelatna tvar acetamiprid.
The said salts can also be prepared from the corresponding salts of Meldonium production intermediates, viz. methyl- or ethyl-esters of 3(2,2,2,-trimethylhydrazinium) propionate, the latter being heated together with the corresponding acids in aqueous or aqueous-alcoholic solutions, and subsequent treatment, eduction and purification being performed by analogy with the first method of preparation. 
Spomenute soli mogu se također proizvesti iz odgovarajućih soli meldonija koje su proizvodni intermedijati, odnosno iz metil- ili etil-estera 3 (2,2,2-trimetilhidrazinij) propionata, pri čemu se potonji grije zajedno s odgovarajućim kiselinama u vodenim ili vodeno-alkoholnim otopinama, i zatim obradom, odvajanjem i čišćenjem, pri čemu se to provodi analogno prvoj metodi proizvodnje.
The siliconized container means of claim 1 wherein the buffer is succinate at a final concentration of 1 mM to 10 mM and pH 5.8 to 6.0. 
Silikonizirani spremnik u skladu s patentnim zahtjevom 1, naznačen time što je pufer sukcinat u konačnoj koncentraciji od 1 mM do 10 mM i pH 5,8 do 6,0.
There is also described herein, compounds of the following formulae:- and 
HR P20080057 T3 Ovdje su također opisani spojevi sljedeće formule: b
A neutralising antibody having specificity for human IL-17, having a heavy chain comprising the sequence given in SEQ ID NO:2 and a light chain comprising the sequence given in SEQ ID NO:4. 
Neutralizirajuće antitijelo koje ima specifičnost za ljudski IL-17, naznačeno time da ima teški lanac koji sadrži sekvencu prikazanu u SEQ ID NO:2 i laki lanac koji sadrži sekvencu prikazanu u SEQ ID NO:4.